Home > Insider Trading > Filing (0001048477-24-000018)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1048477	Biomarin Pharmaceutical Inc	BMRN	Pharmaceutical Preparations (2834)	680397820

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1221590	Jacques Jean Bienaime	C/O Biomarin Pharmaceutical Inc. 770 Lindaro Street San Rafael CA 94901		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-02-27	82,700	$0.00	502,302	No	4	A	Direct
Common Stock	Acquisiton	2024-02-27	35,975	$0.00	538,277	No	4	A	Direct
Common Stock	Acquisiton	2024-02-27	24,926	$0.00	563,203	No	4	A	Direct
Common Stock	Disposition	2024-02-27	1,000	$90.35	562,203	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	247,333	Indirect	Shares held by Jean-Jacques Bienaime Family Trust
Common Stock	100	Indirect	Shares held as UTMA custodian for child 1
Common Stock	100	Indirect	Shares held as UTMA custodian for child 2

Footnotes

Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.